Intranasal administration of neuropeptide Y; development of a novel treatment for major depressive disorder

被引：0
|
作者：
Mathe, A. A. [1 ]
Berg, E. [1 ]
Michaneck, M. [1 ]
Charney, D. S. [2 ]
Murrough, J. W. [3 ]
机构：
[1] Karolinska Inst, Clin Neurosci, Stockholm, Sweden
[2] Icahn Sch Med Mt Sinai, Off Dean, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Psychiat, New York, NY 10029 USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2020年 / 40卷
关键词：
D O I：
10.1016/j.euroneuro.2020.09.184
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.245
引用
收藏
页码：S139 / S140
页数：2
相关论文
共 50 条
  • [41] The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
    Dijkstra, Francis M.
    van de Loo, Aurora Jae
    Abdulahad, Smedra
    Bosma, Else R.
    Hartog, Mitch
    Huls, Hendrikje
    Kuijper, Dianne C.
    de Vries, Esther
    Solanki, Bhavna
    Singh, Jaskaran
    Aluisio, Leah
    Zannikos, Peter
    Stuurman, Frederik E.
    Jacobs, Gabriel E.
    Verster, Joris C.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (05) : 614 - 625
  • [42] DEPRESSIVE PERSONALITY AND TREATMENT OUTCOME IN MAJOR DEPRESSIVE DISORDER
    Ryder, Andrew G.
    Quilty, Lena C.
    Vachon, David D.
    Bagby, R. Michael
    [J]. JOURNAL OF PERSONALITY DISORDERS, 2010, 24 (03) : 392 - 404
  • [43] Development of major depressive disorder during smoking-cessation treatment
    Borrelli, B
    Niaura, R
    Keuthen, NJ
    Goldstein, MG
    DePue, JD
    Murphy, C
    Abrams, DB
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 (11) : 534 - 538
  • [44] Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations
    Pompili, Maurizio
    Sarli, Giuseppe
    Erbuto, Denise
    Manfredi, Giovanni
    Comparelli, Anna
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (03) : 195 - 200
  • [45] The Role of Systemic Inflammation in Major Depressive Disorder and Implications for Novel Treatment Approaches
    Frueh, B. Christopher
    Danner, Summer G.
    Madan, Alok
    Weinstein, Benjamin
    Newlin, Elizabeth
    Taylor, Leslie
    Fowler, J. Christopher
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 254 : 139 - 140
  • [46] The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder
    Liebowitz, Michael
    Croft, Harry A.
    Kajdasz, Daniel K.
    Whalen, Heidi
    Gallipoli, Susan
    Athanasiou, Maria
    Reed, Carol R.
    [J]. PSYCHOPHARMACOLOGY BULLETIN, 2011, 44 (03) : 15 - 33
  • [47] Targeting the ferroptosis crosstalk: novel alternative strategies for the treatment of major depressive disorder
    Wang, Luyao
    Xu, Rongyang
    Huang, Chengying
    Yi, Guozhong
    Li, Zhiyong
    Zhang, Huayang
    Ye, Rongxu
    Qi, Songtao
    Huang, Guanglong
    Qu, Shanqiang
    [J]. GENERAL PSYCHIATRY, 2023, 36 (05)
  • [48] Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
    Carter, Maximilian
    Solsrud, Kassandra
    Mischel, Nicholas
    [J]. FRONTIERS IN PSYCHIATRY, 2022, 13
  • [49] Response to a recently published systematic review on intranasal esketamine for major depressive disorder
    David, Sholto
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2020, 273 : 16 - 17
  • [50] Novel glutamatergic agents for major depressive disorder and bipolar disorder
    Machado-Vieira, Rodrigo
    Ibrahim, Lobna
    Henter, Loline D.
    Zarate, Carlos A., Jr.
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 100 (04) : 678 - 687
12345